(Q24653360)

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

published in

Monoclonal Antibodies

0 references

volume

1

0 references

issue

2

0 references

page(s)

179-84

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

Commentary: practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

Molecular engineering and design of therapeutic antibodies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

Considerations for the development of therapeutic monoclonal antibodies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

Upstream processes in antibody production: evaluation of critical parameters

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

Development trends for monoclonal antibody cancer therapeutics.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

Process economics of industrial monoclonal antibody manufacture

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2725420

What's fueling the biotech engine?

28 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.4161%2FMABS.1.2.7736

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.4161%2FMABS.1.2.7736

From clinical trials to clinical practice: bridging the GAP

21 January 2018

1 reference

12 December 2020

Tysabri's troubles return

1 reference

12 December 2020

Weighing the outcomes

1 reference

12 December 2020

Tier 4 drugs and the fraying of the social compact

1 reference

12 December 2020

Antibody-drug conjugates ace the tolerability test

1 reference

12 December 2020

Trouble at the office

1 reference

12 December 2020

Toward biosimilar monoclonal antibodies

1 reference

12 December 2020

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab

1 reference

12 December 2020